https://www.selleckchem.com/pr....oducts/tunicamycin.h
nse to chemotherapy in CRLM, which may assist in subsequent personalized treatment decision-making in CRLM management. The developed DL-based radiomics model could improve the efficiency to predict the response to chemotherapy in CRLM, which may assist in subsequent personalized treatment decision-making in CRLM management.This analysis represents the longest-term follow-up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for i
Curtir
Comentario
Compartilhar
